Podcast Episodes
Back to Search
Experts Answer FAQs on Biomarker-Driven Therapy for Non-Small-Cell Lung Cancer
Episode 61
In this episode, Nathan Pennell, MD, PhD; Jamie E. Chaft, MD; and Stephen V. Liu, MD, answer questions asked by an audience of healthcare professiona…
5 years, 1 month ago
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC
Episode 60
In this episode,Egbert F. Smit, MD, PhD; David Planchard, MD, PhD; and Helena A. Yu, MD, answer audience questions from a live webinar regarding cli…
5 years, 1 month ago
Immunotherapy for Advanced HCC: Case Series
Episode 59
In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations key considerations for hepatologists, oncologists, and othe…
5 years, 1 month ago
Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From Germany
Episode 58
In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma in…
5 years, 1 month ago
Managing Toxicities Associated With FGFR Inhibitors in Urothelial Cancer and Beyond
Episode 57
In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss toxicities associated with FGFR inhibitors used in the treatment …
5 years, 1 month ago
Optimizing the Timing and Sequencing of Regorafenib and TAS-102 for Patients With Metastatic Colorectal Cancer
Episode 56
In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients w…
5 years, 2 months ago
Expert Answers to Questions on Contemporary Management of Multiple Myeloma
Episode 55
In this episode, Shaji K. Kumar, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD, and Jesús F. San-Miguel, MD, PhD, answer au…
5 years, 2 months ago
Combining PARP inhibitors With Other Treatments for Men With Prostate Cancer: Clinical Trial Updates
Episode 54
In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, consider the potential implications of ongoing and planned clinical trials using …
5 years, 2 months ago
Rationale for Combining PARP Inhibitors With Other Therapies in Prostate Cancer
Episode 53
In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the underlying rationale for using PARP inhibitors in combination with ot…
5 years, 2 months ago
Expert Insight on Key Data From SGO 2021 Informing Treatment for Endometrial and Ovarian Cancer
Episode 52
In this episode, Jubilee Brown, MD, and Ursula Matulonis, MD, provide expert perspectives on new data from SGO 2021 presented for endometrial and ova…
5 years, 2 months ago